Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030562 · ClinicalTrials.gov registry record
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
A clinical trial of Papilloma Viral Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1,321
- Enrollment target
- 7
- Study locations
NCT01030562: Completed study of Papilloma Viral Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01030562 is a study of Papilloma Viral Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,321 participants. The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01030562, a study of Papilloma Viral Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1,321 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to gain a better understanding of the body's response to a human papillomavirus (HPV) (sexually transmitted disease), vaccine and booster shot. The study will also determine factors related to adolescents not following vaccination schedules. The HPV vaccine requires 3 doses (shots). Girls sometimes receive the 3 shots at the recommended time and sometimes girls receive the shots at non-recommended times. This study will evaluate if getting the shots at non-recommended times affects the level of protection provided by the vaccine. Participants will include about 1400 girls 9-17 years old receiving a third dose of HPV vaccine from their primary care clinician. The parent/legal guardian of each subject may answer a questionnaire related to the vaccine schedule. Study procedures include: medical history, questionnaires and blood draws. Participants will be involved in the study for about 6 months from time of enrollment.
Conditions Studied
Study Locations (7)
Georgia
- Kaiser Permanente Crescent Medical Center - Pediatrics/Adolescent Medicine - Tucker
Maryland
- University of Maryland School of Medicine - Center for Vaccine Development - Baltimore - Baltimore
Missouri
- Children's Mercy Hospital and Clinics - Infectious Diseases - Kansas City
Ohio
- Cincinnati Children?s Hospital Medical Center - Adolescent Medicine - Cincinnati
Pennsylvania
- Primary Physicians Research Inc. - Pittsburgh - Pittsburgh
Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt - Adolescent Medicine - Nashville
Washington
- Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,321 participants |
| Start Date | 2010-06-02 |
| Est. Completion | 2014-03-05 |
What the finished NCT01030562 record still lists
NCT01030562 is an observational study that tracks outcomes without assigning an intervention. Its 1,321 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Papilloma Viral Infection appearing as the primary indexed condition, and to 0 interventions.
NCT01030562 lists 7 locations in 7 states (Georgia, Maryland, Missouri).
Frequently Asked Questions
What is clinical trial NCT01030562 about?
NCT01030562 is a clinical study titled "Immunogenicity of Off-Schedule Dosing of HPV Vaccine". The purpose of this study is to gain a better understanding of the body's response to a human papillomavirus (HPV) (sexually transmitted disease), vaccine and booster shot. The study will also determine factors related to adolescents not following vaccination schedules. The HPV vaccine requires 3 do...
What is the current status of trial NCT01030562?
This trial is currently completed. The enrollment target is 1,321 participants. The study started on 2010-06-02. Estimated completion is 2014-03-05.
What conditions does trial NCT01030562 study?
This clinical trial studies the following conditions: Papilloma Viral Infection.
Who is sponsoring clinical trial NCT01030562?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01030562 being conducted?
This trial has 7 study locations across Georgia, Maryland, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papilloma Viral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06557005 · 1,320 participants · NA
Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions
- NCT07213908 · 1,320 participants · NA
Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth
- NCT07144800 · 1,319 participants · NA
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
- NCT05097287 · 1,324 participants · Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI